P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Landi, Lorenza; D’Incà, Federica; Cortesi, Enrico; Chiari, Rita; Grossi, Francesco; Delmonte, Angelo; Marinis, Filippo de; Signorelli, Diego; Dazzi, Claudio; Sperandi, Francesca; Catino, Annamaria; Giannarelli, Diana; Parra, Héctor Soto; Minuti, Gabriele; Bordi, Paola; Migliorino, Maria Rita; Palla, Antonio; Tonini, G.; Cognetti, Francesco; Santoro, Armando; Tassinari, Davide; Scoppola, Alessandro; Bidoli, Paolo; Piantedosi, Franco Vito; Maio, Michele; Crinò, Lucio; Cappuzzo, Federico

doi:10.1016/j.jtho.2018.08.609

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone metastases are associated with poor survival in lung cancer. 31 In the subgroup analysis of the Nivolumab Italian Expanded Access Program, 32 the presence of bone metastases was associated with a worse outcome in both nonsquamous and squamous NSCLC. The mOS in patients with nonsquamous histology in presence or absence of bone metastases was 7.4 months vs 15.3 months ( p > 0.0001), respectively.…”

Section: Discussionmentioning

confidence: 99%

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

Bassanelli¹,

Ricciuti

Giannarelli³

et al. 2021

Tumori

View full text Add to dashboard Cite

Background: The combination of radiotherapy (RT) and programmed death 1 inhibitors seems to increase antitumor immune responses. Objective: To assess the outcome and the role of the best combination sequence, i.e. immunotherapy given before, during, and/or after RT, in patients with non-small cell lung cancer (NSCLC). Methods: We conducted an observational, retrospective analysis of 95 consecutive patients with advanced NSCLC who received any radiotherapy treatment and nivolumab, as clinically indicated. Median overall survival (OS) and the 95% confidence interval (CI) were estimated with the Kaplan-Meier method. Cox model was used to obtain hazard ratio (HR) and associated 95% CI with statistical inference by log-rank statistic. Results: Median OS was 11.9 months (95% CI, 6.6–17.2). Patients who received radiotherapy during an immune checkpoint inhibitor treatment started more than 60 days before showed a better outcome than patients who started immunotherapy over 60 days after RT ending (HR, 2.90 [1.37–6.12], p = 0.005; median OS, 22.4 months vs 8.6 months, p = 0.005). Median progression-free survival was 6.3 months (95% CI, 4.6–8.0). Conclusions: This study shows that combining irradiation with nivolumab for the treatment of advanced NSCLC leads to improved OS. The optimal time window for the combination of RT and immunotherapy seems to play a critical role for therapeutic antitumor response derived by abscopal effect.

show abstract

Section: Discussionmentioning

confidence: 99%

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

Bassanelli¹,

Ricciuti

Giannarelli³

et al. 2021

Tumori

View full text Add to dashboard Cite

show abstract

Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer

Zu,

He,

Zhou

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

Metastasis remains major cause of treatment failure in non-small cell lung cancer (NSCLC). A comprehensive characterization of the transcriptomic landscape of NSCLC-cells with organ-specific metastatic potentials would advance our understanding of NSCLC metastasis process. In this study, we established NSCLC bone-metastatic (BoM), brain-metastatic (BrM), and lymph-metastatic (LnM) cells by an in vivo spontaneous metastatic model. Subsequently, by analyzing the entire transcriptomic profiles of BoM, BrM, LnM, LuM, in comparison with their parental cell line L9981, we identified miR-660-5p as a key driver that is associated with NSCLC progression and distant metastasis, potentially through its targeting of LIMCH1, SMARCA5 and TPP2. In addition, a six-gene signature (ADRB2, DPYSL2, IL7R, LIMCH1, PIK3R1, and SOX2) was subsequently established to predict NSCLC metastasis based on differentially expressed genes, three of which (DPYSL2, PIK3R1, LIMCH1) along with the transcriptional factors RB1 and TP63, were ultimately validated by experiments. Taken together, aberrant gene signature and miRNA can serve as biomarkers for predicting NSCLC distant metastasis, and targeting them could potentially contribute to the development of novel therapeutic strategies.

show abstract

P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Cited by 2 publications

References 0 publications

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

Identification of multiple organ metastasis-associated hub mRNA/miRNA signatures in non-small cell lung cancer

Contact Info

Product

Resources

About